Can immunohistological analysis of transbronchial biopsy specimens predict responder status in early acute rejection of lung allografts?
Acute cellular rejection (ACR) in the early posttransplant period is recognized as one predictor of the development of bronchiolitis obliterans in lung transplant recipients. Using an immunohistochemical panel of antibodies to CD3, L26, HLA-DR, collagenase IV, proliferating cell nuclear antigen (PCNA), KPI, and S100 antigens we analyzed cases of moderate ACR that did respond (n = 11) and that did not respond (n = 10) to bolus solumedrol therapy early in the postoperative period (< 100 days) to determine if we could identify predictors of histological response. Responders who had follow-up negative biopsies after therapy had biopsy specimens containing an average of 41.1% T cells (range, 15.1 to 69.8), 8.8% B cells (range, 0.6 to 20), 18.1% HLA-DR-positive cells (range, 3 to 29.6), 12.2% PCNA-positive cells (range, 2.7 to 22.6), 8.9% collagenase IV-positive cells (range, 0.7 to 20.9), and rare dendritic cells. Nonresponders who had follow-up biopsies that failed to show a significant change in rejection grade had biopsy specimens with the following average cell profiles: 35.8% T cells (range, 7 to 70.7), 21.6% B cells (range, 3.7 to 39.5), 14.2% HLA-DR-positive cells (range, 1.8 to 24.7), 11.4% PCNA-positive cells (range, 0.8 to 22), 12.6% collagenase IV-positive cells (range, 0.6 to 34.1), and occasional dendritic cells. Statistical analysis suggested that large numbers of B lymphocytes in early acute rejection predicts non-responsiveness to interventional immunosuppressive therapy and may indicate a significant role of humoral rejection in the behavior of early allograft rejection.
Yousem
S A
SA
Department of Pathology, Montefiore University Hospital, Pittsburgh, PA 15213-2582.
Martin
T
T
Paradis
I L
IL
Keenan
R
R
Griffith
B P
BP
D000911:Antibodies, Monoclonal; D001706:Biopsy / Q000379:methods; D001989:Bronchiolitis Obliterans / Q000517:prevention & control; D006084:Graft Rejection / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D016130:Immunophenotyping; D016040:Lung Transplantation / Q000276:immunology* / Q000473:pathology; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D011379:Prognosis; D014184:Transplantation, Homologous / Q000276:immunology
D000911:Antibodies, Monoclonal; D008776:Methylprednisolone Hemisuccinate